Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer
Oral Diseases (2010) 16, 360–364 Backgrounds: Oral squamous cell carcinoma (OSCC) is a worldwide disease. MicroRNAs are endogenously expressed non‐coding RNAs that have important biological and pathological functions. miR‐31 was found markedly up‐regulated in OSCC and several other malignancies. Ho...
Gespeichert in:
Veröffentlicht in: | Oral diseases 2010-05, Vol.16 (4), p.360-364 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Oral Diseases (2010) 16, 360–364
Backgrounds: Oral squamous cell carcinoma (OSCC) is a worldwide disease. MicroRNAs are endogenously expressed non‐coding RNAs that have important biological and pathological functions. miR‐31 was found markedly up‐regulated in OSCC and several other malignancies. However, miR‐31 expression was also down‐regulated in the metastasis process of breast carcinoma.
Materials and methods: Using quantitative RT‐PCR analysis, we identified plasma miR‐31 in OSCC patients (n = 43) and case controlled individuals (n = 21). Nine OSCC patients saliva were also analyzed. The Mann–Whitney test and Wilcoxon matched pairs test were used to compare the differences among the various clinical variants.
Results: miR‐31 in plasma was significantly elevated in OSCC patients relative to age and sex‐matched control individuals. This marker yielded a receiver operating characteristic curve area of 0.82 and an accuracy of 0.72 defined by leave‐one‐out cross‐validation. In addition, the plasma miR‐31 in patients was remarkably reduced after tumor resection suggesting that this marker is tumor associated. Our preliminary analysis also demonstrated the feasibility of detecting the increase of miR‐31 in patient’s saliva.
Conclusion: This study concluded that plasma miR‐31 could be validated a marker of OSCC for diagnostic uses. |
---|---|
ISSN: | 1354-523X 1601-0825 |
DOI: | 10.1111/j.1601-0825.2009.01646.x |